Research Article
MERKEZİMİZE BAŞVURAN NONVALVÜLER ATRİYAL FİBRİLASYONLU HASTALARIN DEMOGRAFİK ÖZELLİKLERİNİN VE ORAL ANTİKOAGÜLASYON TERCİHLERİNİN RETROSPEKTİF OLARAK DEĞERLENDİRİLMESİ Retrospective Evaluation of Oral Anticoagulation Preferences and Demographic Characteristics of the Patients with Nonvalvular Atrial Fibrillation in Our Center
Abstract
ÖZET
Amaç: Atriyal fibrilasyon (AF) en sık saptanan kardiyak aritmi olup tromboembolik olay oranında 5 kat artışla
ilişkilidir. Yozgat popülasyonunda non-valvüler AF nedeniyle hastaneye başvuru sıklığı, risk faktörlerinin
varlığı, uygulanan antikoagülan–antitrombotik tedavinin seçimi hakkında literatürde yeterli veri yoktur. Bu
çalışmada, Yozgat ilinde yaşayan non-valvüler AF’li hastaların demografik özelliklerini, antikoagülan–antitrombotik
tedavi seçimini ve iskemik inme gelişim riskini değerlendirmeyi amaçladık.
Metod: Bozok Üniversitesi Tıp Fakültesi Hastanesi Kardiyoloji polikliniğine başvuran 18 yaş üstü nonvalvüler
AF tanılı 316 kişinin bilgileri retrospektif olarak incelendi. Hastaların bazal demografik verileri, inme
risk faktörleri ve kullanmış oldukları antiagregan–antikoagülan tedavileri değerlendirildi.
Bulgular: Hastaların 130’u (%41) erkek ve 186’sı (%59) kadın bireylerden oluşmaktaydı. Hastaların yaş ortalaması
67,5±12,9 yıldı. Ortalama CHA2DS2-VASC skoru 3,2±1,3 olarak bulundu. AF’ye eşlik eden inme risk
faktörleri sıklık sırasına göre yaş, hipertansiyon, vasküler hastalıklar, kalp yetmezliği ve diyabetes mellitus
olarak bulundu.
Sonuç: Hastaların büyük çoğunluğunun oral antikoagülan (OAK) kullandığı gözlenmiştir. Fakat hala azımsanmayacak
şekilde OAK tedavisi almayan ya da eksik tedavi alan hastalarında olduğu da tespit edilmiştir.
Anahtar Sözcükler: Atriyal fibrilasyon; Oral antikoagülan; Risk skorları
References
- 1. Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. EurHeart J. 2013;34(35):2746–51. 2. Macle L, Cairns J, Leblanc K, Tsang T, Skanes A, Cox JL et al. CCS Atrial Fibrillation Guidelines Committee. 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2016 Oct;32(10):1170-85. 3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, OldgrenJ , Parekh A, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51. 4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. 5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. 6. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104. 7. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263-72. 8. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH,et al. ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. EurHeart J. 2012 Nov;33(21):2719-47. 9. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. EurHeart J. 2016 Oct7;37(38):2893-962. Epub 2016 Aug 27. 10. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22: 983-8.
Year 2018,
Volume: 8 Issue: 2, 15 - 20, 29.06.2018
Abstract
References
- 1. Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. EurHeart J. 2013;34(35):2746–51. 2. Macle L, Cairns J, Leblanc K, Tsang T, Skanes A, Cox JL et al. CCS Atrial Fibrillation Guidelines Committee. 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2016 Oct;32(10):1170-85. 3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, OldgrenJ , Parekh A, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51. 4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. 5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. 6. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104. 7. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263-72. 8. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH,et al. ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. EurHeart J. 2012 Nov;33(21):2719-47. 9. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. EurHeart J. 2016 Oct7;37(38):2893-962. Epub 2016 Aug 27. 10. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22: 983-8.
There are 1 citations in total.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Original Research |
| Authors | |
| Publication Date | June 29, 2018 |
| Published in Issue | Year 2018 Volume: 8 Issue: 2 |
Cite
Copyright © BOZOK Üniversitesi - Tıp Fakültesi